TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06038461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib Combined With Temozolomide and S-1
Description: Phase I:~Surufatinib: 250mg, QD, PO, Q3W; Temozolomide: 200-300mg, d10-d14, QD, PO, Q3W; S-1: 40-60mg, d1-d14, BID, PO, Q3W.~Phase II:~Surufatinib, Temozolomide and S-1：RP2D
Study: NCT05283343

Intervention type: DEVICE
Intervention: SP-1P
Description: A subject undergoes corneal thickness measurement with pachymeter.
Study: NCT04286581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Gel Laryngeal Mask Airway
Description: The I-Gel Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu Auragain Laryngeal Mask Airway
Description: The Ambu Auragain Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.
Study: NCT04757610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.0 mg OPT-302
Description: intravitreal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.0 mg OPT-302
Description: intravitreal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Description: intravitreal injection
Study: NCT04612751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
Study: NCT04757610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Description: intravitreal injection

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: 0.5 mg ranibizumab
Description: intravitreal injection

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: intravitreal injection
Study: NCT04612751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
Study: NCT06240702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Group
Description: Unlike the control group, the experimental group will be given a phase II telerehabilitation program and sleep hygiene training for 3 weeks after discharge. Within the scope of the Phase II telerehabilitation program, breathing exercises and calisthenic exercises will be performed at increasing intensity according to the patient's tolerance, 3 days a week for 3 weeks. In addition, walking training will be continued over increasing distances. In addition, it will be aimed to increase sleep quality by giving a sleep hygiene education brochure to the patients in the experimental group. During the sessions, the vital signs and clinical status of the patients will be monitored according to the severity level determined by the finger pulse oximeter device, digital blood pressure monitor, perceived difficulty level (Borg Scale) and maximum heart rate. In addition, patients will be kept in a diary to monitor their compliance with the treatment program.
Study: NCT06528925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality goggles
Description: Patients in the study group will be shown a video with virtual reality glasses during the procedure. Patients will be asked to wear a virtual reality goggle (VR Box Virtual Reality Headset 3D Vr Glasses V2.0 2020 model) that is compatible with a mobile phone (Xiaomi Redmi Note 8 Pro 2019 model) with android operating system and minimizes sound loss in the supine position. With the virtual reality glasses, nature landscapes with relaxing music background will be watched by adjusting the volume at the level desired by the patient. Virtual reality goggles will be applied during the urodynamic procedure.
Study: NCT05516524

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home sleep apnea test
Description: Level II home sleep apnea testing evaluates for obstructive sleep apnea in the home environment with parental supervision.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PSG
Description: Overnight sleep study in the sleep laboratory with continuous monitoring by clinical staff.
Study: NCT06063148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enrolled Participant
Description: Participant will undergo at most 10 SpO2 measurements paired with at most 10 routine blood gas samples.
Study: NCT06484452

Intervention type: DEVICE
Intervention: No Intervention
Description: No Intervention

Intervention type: DEVICE
Intervention: No Intervention
Description: No Intervention

Intervention type: DEVICE
Intervention: No Intervention
Description: No Intervention

Intervention type: DEVICE
Intervention: No Intervention
Description: No Intervention
Study: NCT06061952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized Adherence Enhancement for Schizophrenia (CAE-S)
Description: 6-session series spaced out over approximately 6-10 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Treatment as Usual (eTAU)
Description: eTAU participants will view a pre-taped series of 6 videos
Study: NCT05338775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered as a subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered as a subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered as a SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered as a SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitor
Description: The PD-1 inhibitor will be administered as an intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitor
Description: The PD-1 inhibitor will be administered as an intravenous injection.
Study: NCT06522997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: Tablet, intake orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: Tablet, intake orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: Tablet, intake orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: Tablet, intake orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: Tablet, intake orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching with BAY3283142
Study: NCT05116722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoulder Pacemaker
Description: Shoulder pacemaker treatment for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.
Study: NCT06435143

Intervention type: DEVICE
Group type: OTHER
Intervention: Prelivia
Description: Pad applied to skin provide electrical stimulation for 10 seconds every 10 minutes
Study: NCT05851313

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin-D
Description: The intervention group received 600IU of vitamin D supplements every day, one hour after breakfast for 14-16 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vitamin-D
Description: The intervention group received 600IU of vitamin D supplements every day, one hour after breakfast for 14-16 weeks.
Study: NCT05389254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous glucose monitoring system
Description: use real-time CGM system to check and adjust blood glucose

Intervention type: DEVICE
Group type: OTHER
Intervention: capillary blood glucose monitoring
Description: monitor blood glucose with finger blood; real-time CGM is blind to both participants and researchers
Study: NCT05193916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chiglitazar sodium tablets
Description: the drugs will be given orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chiglitazar sodium tablets
Description: the drugs will be given orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active drug contained
Study: NCT05342051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balneotherapy
Description: immersion in radon, calcium, natrium, bicarbonate content 42 ℃ thermal-mineral water 15 times in 3 weeks, plus usual care. The total mineral substance of the water is 1530 mg/l. The suggested daily time spent in water is 20 minutes altogether with breaks.
Study: NCT04875702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: For the TTT-SU group: The dose titration algorithm for allopurinol increases every 4 weeks by 100 mg until the target serum urate of 6 mg/dL is reached or a patient requires 800 mg per day of allopurinol. Subjects will require a blood draw for SU every 4 weeks until reaching the target.~For the TTASx group: Subjects randomized to the TTASx group will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone) for up to six flares over the ensuing three months. Urate lowering therapy (ULT) will only be offered after the third flare during the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: For the TTT-SU group: The dose titration algorithm for allopurinol increases every 4 weeks by 100 mg until the target serum urate of 6 mg/dL is reached or a patient requires 800 mg per day of allopurinol. Subjects will require a blood draw for SU every 4 weeks until reaching the target.~For the TTASx group: Subjects randomized to the TTASx group will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone) for up to six flares over the ensuing three months. Urate lowering therapy (ULT) will only be offered after the third flare during the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 250 MG
Description: Naproxen 250 mg p.o. twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 250 MG
Description: Naproxen 250 mg p.o. twice daily
Study: NCT05256095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thinking in Speech
Description: Thinking in Speech is a therapy to help children with autism learn to cope with daily stressors and improve their communication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thinking in Speech
Description: Thinking in Speech is a therapy to help children with autism learn to cope with daily stressors and improve their communication.
Study: NCT06585631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CC PrTNER
Description: Participants randomized to CC PrTNER will be assigned a peer coach. They will conduct interviewer-administered behavioral surveys. The surveys provide an in-depth assessment of SU, HIV prevention and care, engagement, and adherence. Behavioral surveys are administered monthly. The coach will discuss with the participant the areas that are flagged by the psychiatrist; provide psychoeducation around areas identified, and work with the participant to identify their health goals and how changes in SU may help feed into self-defined goals. The coach will meet weekly with the consultant addiction psychiatrist who will make a provisional diagnosis and define a treatment plan with clear goals for treatment outcome. Recommendations will be communicated electronically to the HIV or PrEP provider to facilitate implementation. The coach utilizes MI skills to implement the individually tailored to facilitate the adoption and maintenance of health behaviors.
Study: NCT06362902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic right hemicolectomy with transrectal specimen extraction
Description: Laparoscopic right hemicolectomy with transrectal specimen extraction
Study: NCT04764864

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angioembolization
Description: Via the femoral route, a non-selective pelvic arteriography with a selective embolization of the arterial branches that show direct or indirect signs of injury will be performed.~In the event of persistent hemodynamic instability after selective embolization, non-selective bilateral embolization of the internal iliac arteries will be evaluated.~The material used will vary depending on the characteristics of the injury and the availability of the materials.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preperitoneal Pelvic Packing
Description: Pfannestiel incision / infraumbilical laparotomy. Dissection of tissues up to and including the transversalis fascia. Inferior to this and anterior to the peritoneum, the preperitoneal cavity is identified.~Inclusion of radiopaque laparotomy gauze in each hemipelvis, from the posterior part (anterior to the sacro-iliac joint) to the most anterior in the retropubic position. Subsequently, the closure is carried out to increase the plugging effect.~A second intervention is required to remove the material in 24-48 hours.
Study: NCT05065892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAX
Description: 2 doses of Covid-19 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAX
Description: 2 doses of Covid-19 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVAX
Description: 2 doses of Covid-19 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAX
Description: 2 doses of Covid-19 vaccine
Study: NCT04465825

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HITT: intermittent high intensity exercise
Description: Intermittent bouts of 30-60 seconds of exercise at 90% of peak intensity (HITT).
Study: NCT05574010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 in Part A
Description: Dose 1 KAN-101 Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 in Part A
Description: Dose 2 KAN-101 Intravenous (IV) infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Group 1 in Part B and Part C
Description: Placebo Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2 in Part B and Part C
Description: Dose 3 KAN-101 Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 3 in Part B and Part C
Description: Dose 4 KAN-101 Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 4 in Part B and Part C
Description: Dose 5 KAN-101 Intravenous (IV) infusion
Study: NCT06556927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes.
Study: NCT04700488

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6D-MRI
Description: Six-Dimensional Quantitative Dynamic Contrast Enhanced MRI
Study: NCT06335888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaFol
Description: AzaFol-PET/CT imaging

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AzaFol
Description: AzaFol-PET/CT imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDG
Description: FDG-PET/CT imaging

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDG
Description: FDG-PET/CT imaging
Study: NCT06585449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-HTT02
Description: ALN-HTT02 will be administered intrathecally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALN-HTT02
Description: ALN-HTT02 will be administered intrathecally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intrathecally
Study: NCT04875702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.6 mg
Description: Colchicine 0.6 mg p.o. once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 1.2 mg
Description: Dose escalation to 0.6 mg p.o. twice daily for patients experiencing breakthrough flares or a dose decrease (0.6 mg p.o. every other day) for patients experiencing gastrointestinal intolerance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 500 Mg
Description: dose escalation to 500 mg twice daily for patients experiencing breakthrough flares.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone 40 mg
Description: For flare glucocorticoids: prednisone taper for 8 days, starting with 40mg (oral) daily.
Study: NCT06068465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimavanserin tartrate
Description: pimavanserin tartrate, 34 mg, capsule, once daily by mouth for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, capsule, once daily by mouth for 6 weeks
Study: NCT05892744

Intervention type: DRUG
Group type: OTHER
Intervention: Sertraline
Description: 50-200mg/day
Study: NCT05834777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: Icatibant will be administered with an infusion rate of 100µg/kg/h for 15 minutes before their hemodialysis session (pre-infusion) and 50µg/kg/h during their routine hemodialysis session (maintenance infusion).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride will be administered as the same rate as icatibant
Study: NCT05092269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab will be administered as a SC injection.
Study: NCT06572423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized ultrafractionated stereotactic adaptive radiotherapy
Description: PULSAR is a radiation therapy regimen that uses a limited number of fairly large dose pulses while adjusting to specific anatomic and/or biological changes which may occur during the course of the treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volume Modulated Arc Therapy
Description: Use HyperArc technology

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT simulation for radiation planning

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Undergo standard of care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: University of Washington Quality of Life Scale, Version 4
Description: Complete questionnaire

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-Head & Neck
Description: Complete questionnaire
Study: NCT05650879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELVN-002
Description: capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELVN-002
Description: capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELVN-002
Description: capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELVN-002
Description: capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELVN-002
Description: capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fam-Trastuzumab Deruxtecan-Nxki
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: intravenous